本文選題：艾滋病 + 脾虛濕盛��； 參考：《中華中醫(yī)藥雜志》2017年09期

【摘要】：目的:觀察湘A1號(hào)顆粒治療艾滋病的臨床療效及安全性,探討湘A1號(hào)顆粒治療艾滋病的相關(guān)機(jī)制。方法:采用雙盲雙模擬設(shè)計(jì),將60例艾滋病脾虛濕盛型患者隨機(jī)分為3組,每組20例。湘A1號(hào)組予湘A1號(hào)顆粒加抗病毒藥物安慰劑;抗病毒組予抗病毒藥物加湘A1號(hào)顆粒安慰劑;聯(lián)合組予湘A1號(hào)顆粒加抗病毒藥物;連續(xù)治療6個(gè)月。治療結(jié)束后通過癥狀體征積分、病毒載量、T細(xì)胞亞群進(jìn)行療效分析。結(jié)果:3組均能有效改善癥狀體征、提高生活質(zhì)量(P0.05),湘A1號(hào)組與抗病毒組無顯著差異,聯(lián)合組優(yōu)于湘A1號(hào)組和抗病毒組(P0.05);聯(lián)合組與抗病毒組治療前后病毒載量計(jì)數(shù)下降明顯(P0.01),且抗病毒作用優(yōu)于湘A1號(hào)組(P0.01);湘A1號(hào)組和聯(lián)合組患者CD45RA+、CD45RA+CD3+、CD45RA+CD28+、CD45RA+CD4+、CD45RA+CD25+百分率及CD4/CD8比值顯著上升(P0.01),抗病毒組CD45RA+、CD45RA+CD3+、CD45RA+CD4+百分率及CD4/CD8比值顯著上升(P0.01),湘A1號(hào)組和聯(lián)合組治療后CD45RA+、CD45RA+CD3+、CD45RA+CD28+、CD45RA+CD4+、CD45RA+CD25+百分率與抗病毒組治療后比較差異有統(tǒng)計(jì)學(xué)意義(P0.01,P0.05)。結(jié)論:湘A1號(hào)顆粒能緩解艾滋病脾虛濕盛型患者的癥狀體征、提高生活質(zhì)量,湘A1顆粒與抗病毒療法聯(lián)用有協(xié)同作用;湘A1號(hào)顆�？共《咀饔貌幻黠@,但具有明顯免疫重建作用。
[Abstract]:Objective: to observe the clinical efficacy and safety of XiangA1 granule in the treatment of AIDS, and to explore the mechanism of XiangA1 granule in the treatment of AIDS. Methods: 60 AIDS patients with spleen deficiency and dampness were randomly divided into 3 groups with 20 cases in each group. Group A 1 was treated with placebo, group A 1 was treated with anti viral drug and group A 1 was treated with anti viral drug for 6 months. After treatment, the therapeutic effect was analyzed by symptom and sign score and viral load T cell subsets. Results all the three groups were able to improve the symptoms and signs and improve the quality of life (P0.05). There was no significant difference between the Xiang A1 group and the antiviral group. The combined group was superior to the XiangA1 group and the antiviral group (P0.05), the viral load in the combined group and the antiviral group decreased significantly before and after treatment (P0.01), and the antiviral effect was better than that in the XiangA1 group (P0.01); the patients in the XiangA1 group and the combined group were treated with CD45RA, CD45RA, CD28, CD45RA, CD4, CD45RA, CD25. The percentage of CD45RA and the ratio of CD4 / CD8 increased significantly (P0.01), the percentage of CD45RA CD3 CD45RA CD4 and CD4 / CD8 increased significantly in antiviral group (P0.01). After treatment, the percentage of CD45RA, CD45RA, CD28, CD45RA, CD4, CD45RA and CD25 in group A 1 and group A were significantly higher than those in group B (P 0.01 P 0.05). Conclusion: XiangA1 granule can alleviate the symptoms and signs of patients with spleen deficiency and dampness and improve the quality of life. XiangA1 granule has synergistic effect with antiviral therapy, but XiangA1 granule has no obvious antiviral effect. But it has obvious immune reconstruction effect.
【作者單位】： 湖南中醫(yī)藥大學(xué)第二附屬醫(yī)院;湖南中醫(yī)藥大學(xué);衡陽市第三人民醫(yī)院;湖南省新開鋪強(qiáng)制隔離戒毒所醫(yī)院;
【基金】：湖南中醫(yī)藥大學(xué)感染性疾病中醫(yī)藥防治研究團(tuán)隊(duì)基金計(jì)劃項(xiàng)目(No.Crxjb-12) 湖南省教育廳中醫(yī)外科學(xué)重點(diǎn)學(xué)科專項(xiàng)基金資助 湖南省科技廳課題(No.2013SK3097)~~
【分類號(hào)】：R512.91

【相似文獻(xiàn)】

相關(guān)碩士學(xué)位論文 前1條

1 苗慧;復(fù)方芪術(shù)湯聯(lián)合高效抗反轉(zhuǎn)錄病毒治療脾虛濕盛型艾滋病的臨床研究[D];復(fù)旦大學(xué);2014年

，

本文編號(hào)：2109045